Eli Lilly and Company, maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has said that its investigational drug ...

The partnership will bring together Apollo’s clinical ecosystem with BITS Pilani’s expertise in engineering, technology and ...

The filing seeks approval of fenebrutinib for adults with relapsing multiple sclerosis (RMS) and primary progressive multiple ...

The initiative will target hospitals, diagnostic centres, research institutions and smaller healthcare facilities ...

French biotechnology company Abolis Biotechnologies has launched MINE (Microbial INtelligence Explorer), a new ...

Novel, non-steroidal topical PDE4 inhibitor is approved for adults and pediatric patients aged 2 years and older ...

The study’s primary endpoint was the proportion of patients achieving at least a 75% improvement from baseline in the Eczema ...

The analysis found that people taking Zepbound (tirzepatide) 15 mg lost an average of 4.5% more body weight than those taking Wegovy HD (semaglutide 7.2 mg) after 72 weeks ...

The deal includes a $300 million upfront payment, with the remaining value tied to development, regulatory and commercial ...

AstraZeneca will take a roughly 12% stake in Summit Therapeutics under a deal aimed at accelerating development of ...

Eli Lilly has said that its once-daily oral drug Foundayo (orforglipron) 17.2 mg was associated with greater weight loss and ...

First-time-in-India approval strengthens Akums’ presence in the growing cardiovascular therapeutics segment ...